3Skolnick P,Krieter P,Tizzano J,et al.Preclinical and clinical pharmacology of DOV 216,303,a "triple" reuptake inhibitor[J].CNS Drug Rev,2006; 12:123-134.
4Machado-Vieira R,Salvadore G,Diazgranados N,et al.Ket-amine and the next generation of antidepressants with a rapid onset of action[J].Pharmacol Ther,2009;123:143-150.
5Keller M,Montgomery S,Ball W,et al.Lack of efficacy of the substance p (neurokininl receptor) antagonist aprepitant in the treatment of major depressive disorder[J].Biol Psychiatry,2006;59:216-223.
6Furey ML,Drevets WC.Antidepressant efficacy of the antimuscarinic drug scopolamine:a randomized,placebo-controlled clinicaltrial[J].Arch Gen Psychiatry,2006;63:1121 -1129.
7Mottram P,Wilson K,Strobl J.Antidepressants for depressed elderly[J].Cochrane Database Syst Rev,2006;(1):5.
8Schechter LE,Smith DL,Rosenzweig -Lipson S,et al.Lecozotan (SRA-333):a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties[J].J Pharmacol Exp Ther,2005;314:1274-1289.
9Ohayon MM,Schatzberg AF.Using chronic pain to predict depressive morbidity in the general population[J].Arch Gen Psychiatry,2003;60:39-47.
10Lipton SA.Paradigm shift in NMDA receptor antagonist drug development; molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimers disease and other neurologic disorders[J].J Alzheimers Dis,2004;6:61 -74.
